$KOD

Kodiak Sciences Inc (KOD) rose 8.56% on October 15, 2026, following positive Phase 3 DAYBREAK trial results for its treatments Zenkuda and tabirafusp-ted. The trial met primary endpoints, showing vision gains and favorable safety. Analysts raised price targets, with LifeSci Capital setting it at $145. KOD's stock surged over 100% on September 28, 2026, after the trial news. The company remains pre-revenue but has a strong cash position.

Kodiak Sciences (KOD) shares fell 7.84% despite positive Phase 3 trial results, as investors took profits and raised concerns about competition and commercial infrastructure. The company's long-term prospects remain uncertain due to cash burn and funding needs, despite strong clinical data. KOD has a market cap of $6.24B and is up 255.01% YTD.

H.C. Wainwright raised its price target on Kodiak Sciences (NASDAQ:KOD) to $126 from $96, maintaining a Buy rating. The move follows positive Phase 3 DAYBREAK trial results for Zenkuda and Tabirafusp in wet age-related macular degeneration. The trial met its primary endpoint, with Zenkuda showing sustained efficacy. Kodiak plans to submit a Biologics License Application in Q4 2026. The stock is up 741% over the past year, trading at $99.87. Other analysts have mixed outlooks on the company.

Kodiak Sciences' tarcocimab and tabirafusp-ted showed noninferiority to aflibercept in treating wet AMD in the DAYBREAK trial. Tarcocimab improved BCVA by 7.2 letters vs 7.6 for aflibercept, while tabirafusp-ted improved BCVA by 6.3 letters. Kodiak plans to submit a BLA for tarcocimab in 2026, supported by multiple trials.

Kodiak Sciences (KOD) shares rose after presenting positive Phase 3 and Phase 1b data for its eye drugs Zenkuda and KSI-501 at the American Academy of Ophthalmology 2026 meeting. The data showed efficacy and safety in treating wet age-related macular degeneration, boosting investor confidence ahead of a potential regulatory filing. The company has no approved drugs yet and is burning cash, which poses risks.

Kodiak Sciences (KOD) stock surged over 600% in a year, closing at $94.45 on October 2, 2026. The rise was driven by successful Phase 3 trial results for Zenkuda and tabirafusp-ted, which met primary endpoints in treating wet age-related macular degeneration. The company plans to file a biologics license application in Q4 2026 but reported a net loss of $65.6 million in Q2 2026. Analysts have a Strong Buy consensus with an average price target of $116.67.

BAKER BROS. ADVISORS LP increased its stake in Kodiak Sciences Inc (KOD) by 10.69%, acquiring 2.13 million shares at $89.92 each. The firm now owns 35% of KOD, which makes up 9.88% of its portfolio. Kodiak, a clinical-stage biopharmaceutical company, has seen significant stock momentum but reports no product revenue and negative profitability metrics. The stock is currently overbought, with an RSI of 85.27.

Kodiak Sciences reported positive Phase III study results for its wet AMD treatments, Zenkuda and tabirafusp-ted, showing non-inferiority to aflibercept. Zenkuda met primary endpoints, with 54% of patients reaching a 24-week dosing interval. Tabirafusp-ted demonstrated equivalence in visual acuity. The company plans to submit a multi-indication biologics license application for Zenkuda this year and continues Phase III trials for tabirafusp-ted in DME and KSI-101 in macular edema.

Kodiak Sciences (KOD) stock surged 300% to over $100 after positive Phase 3 results for its retinal disease treatments, but has since pulled back below $90. The DAYBREAK study showed Zenkuda met primary endpoints, with plans for a 2026 regulatory submission. Investors are now taking profits, and traders are watching for stabilization.

Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.